Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04156100 · ClinicalTrials.gov registry record · Phase 1
A Study in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Agenus.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04156100 is a Phase 1 study that was terminated before completion, run by Agenus. The registered enrollment target is 19 participants.
The verdict
NCT04156100, a Phase 1 study, was terminated before completion, sponsored by Agenus.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination with balstilimab in subjects with advanced solid tumors.
Interventions
- DRUG AGEN1223
- DRUG AGEN1223 and balstilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2021-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04156100
The ClinicalTrials.gov registry entry for NCT04156100 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AGEN1223 is the first listed.
NCT04156100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04156100 about?
NCT04156100 is a clinical study titled "A Study in Subjects With Advanced Solid Tumors". This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination...
What is the current status of trial NCT04156100?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-12-10. Estimated completion is 2021-09-29.
What interventions are being tested in trial NCT04156100?
The interventions under investigation include: AGEN1223 (DRUG), AGEN1223 and balstilimab (DRUG).
Who is sponsoring clinical trial NCT04156100?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.